查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612713

CD 抗原癌症治疗市场：按治疗类型、CD 抗原类型、癌症类型、最终用户 - 全球预测 2025-2030

CD Antigen Cancer Therapy Market by Therapy Type, Type of CD Antigens, Type of Cancer, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

CD抗原癌症治疗市场2023年估值为104.8亿美元，预计2024年将达到110.9亿美元，复合年增长率为6.17%，到2030年将达到159.4亿美元。

CD 抗原癌症治疗涉及靶向分化簇 (CD) 分子，这些分子是在免疫反应中发挥重要作用的细胞表面蛋白。这些治疗方法在癌症治疗中至关重要，因为它们可以精确靶向癌细胞，同时最大限度地减少对健康组织的损害。对 CD 抗原疗法的需求源于其提高癌症患者生存率和生活品质的潜力，使其成为个人化医疗时代的一种有前途的方法。它已应用于多种癌症类型，包括淋巴瘤和白血病，其中 CD19 和 CD20 等 CD 抗原是有效标靶。主要最终用户包括推动该领域进步的医院、癌症研究机构和生技公司。

主要市场统计
基准年[2023] 104.8亿美元
预测年份 [2024] 110.9亿美元
预测年份 [2030] 159.4亿美元
复合年增长率（%） 6.17%

市场洞察指出了几个成长要素，例如癌症发病率的增加、生物技术的进步以及政府促进癌症研究的支持政策。新的商机在于CD抗原疗法的应用从血液癌扩展固体癌，以及针对多种CD抗原的双特异性抗体和CAR-T细胞疗法的进展。为了利用这些机会，公司必须投资强大的研发开发平臺和策略联盟。然而，市场面临挑战，包括高昂的治疗开发成本、严格的监管环境以及潜在的不良免疫反应。癌症异质性的复杂性也产生了局限性，这可能会降低目标疗效。

有前景的创新途径包括探索 CD 抗原疗法和免疫疗法的联合治疗，以及整合人工智慧主导的方法以提高诊断准确性。对 CD 的新标靶和改进的交付机制的研究可以进一步释放该市场的潜力。市场动态是动态的和竞争性的，要求相关人员保持敏捷，专注于专利策略，并促进合作以维持市场影响。实施数位健康技术来简化临床试验流程并促进以患者为中心的结果可以显着增强业务成长和市场差异化。

市场动态：揭示快速发展的 CD 抗原癌症治疗市场的关键市场洞察

CD 抗原癌症治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症发生率上升
    • 对个人化医疗的兴趣日益浓厚
  • 市场限制因素
    • CD抗原治疗费用高
  • 市场机会
    • 生物技术不断进步，提高 CD 抗原治疗的功效
    • 增加政府对癌症研究的资助和支持
  • 市场挑战
    • 与 CD 抗原治疗相关的替代技术的出现

波特五力：开拓 CD 抗原癌症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 CD 抗原癌症治疗市场的外部影响

外部宏观环境因素在塑造 CD 抗原癌症治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解CD抗原癌症治疗市场的竞争状况

CD抗原癌症治疗市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 CD 抗原癌症治疗市场供应商的绩效评估

FPNV定位矩阵是评估CD抗原癌症治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製 CD 抗原癌症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，CD 抗原癌症治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地各种癌症的发生率正在上升
      • 个人化医疗的趋势日益增长
    • 抑制因素
      • CD抗原治疗高成本
    • 机会
      • 提高 CD 抗原治疗功效的生物技术进步
      • 增加政府对癌症研究的资助和支持
    • 任务
      • 与 CD 抗原治疗相关的替代技术的出现
  • 市场区隔分析
    • 治疗类型：增加抗体药物复合体的使用，以尽量减少化疗对健康细胞的影响
    • 最终使用者：提高提供全面照护的癌症治疗中心 CD 抗原癌症治疗的可近性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 CD 抗原癌症治疗市场（依治疗类型）

  • 抗体药物复合体
  • 双特异性 T 细胞接合器
  • 嵌合体抗原受体T细胞疗法
  • 单株抗体
  • 放射免疫治疗

第7章CD抗原癌症治疗市场（依CD抗原类型划分）

  • 通用抗原
  • 新抗原

第8章依癌症类型分類的CD抗原癌症治疗市场

  • 乳癌
  • 白血病
  • 肺癌
  • 淋巴瘤
  • 多发性骨髓瘤
  • 摄护腺癌

第 9 章 CD 抗原癌症治疗市场：依最终用户分类

  • 癌症治疗中心
  • 医院
  • 调查机构
  • 专科诊所

第十章北美和南美CD抗原癌症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区CD抗原癌症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲CD抗原癌症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Coeptis Therapeutics 在 SITC 2023 上宣布 SNAP-CAR T 细胞癌症治疗的进展
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Illumina, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-9A2BA9536662

The CD Antigen Cancer Therapy Market was valued at USD 10.48 billion in 2023, expected to reach USD 11.09 billion in 2024, and is projected to grow at a CAGR of 6.17%, to USD 15.94 billion by 2030.

CD Antigen Cancer Therapy involves targeting cluster of differentiation (CD) molecules, cell surface proteins that play crucial roles in immune responses. These therapies are pivotal in oncology as they enable precise targeting of cancer cells while minimizing damage to healthy tissue. The necessity of CD antigen therapies stems from their potential to improve survival rates and quality of life for cancer patients, offering a promising approach in the era of personalized medicine. Applications extend across various cancer types, including lymphomas and leukemias, where CD antigens like CD19 and CD20 serve as effective targets. Key end-user segments include hospitals, cancer research institutes, and biotech companies that drive advancements in this field.

KEY MARKET STATISTICS
Base Year [2023] USD 10.48 billion
Estimated Year [2024] USD 11.09 billion
Forecast Year [2030] USD 15.94 billion
CAGR (%) 6.17%

Market insights point to several growth factors, such as increasing cancer prevalence, advancements in biotechnology, and supportive governmental policies promoting cancer research. Emerging opportunities lie in expanding applications of CD antigen therapies beyond hematological cancers to solid tumors, as well as advancements in bispecific antibodies and CAR-T cell therapies targeting multiple CD antigens. It's vital for companies to invest in robust R&D pipelines and strategic collaborations to capitalize on these opportunities. However, the market faces challenges, including high costs of therapy development, stringent regulatory landscapes, and potential adverse immune responses. Limitations also arise from the complexity of cancer heterogeneity, which may reduce targeting efficacy.

For innovation, exploring combination therapies with CD antigenial therapeutics and immunotherapies or integrating AI-driven approaches to enhance diagnostic precision offers promising avenues. Research into novel CD targets and improving delivery mechanisms can further unlock potential in this market. As the CD antigen cancer therapy market is dynamic and competitive, stakeholders must remain agile, focusing on patent strategies and fostering collaborations to sustain market presence. Embracing digital health technologies to streamline clinical trial processes and promote patient-centric outcomes can significantly enhance business growth and market differentiation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving CD Antigen Cancer Therapy Market

The CD Antigen Cancer Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of a number of cancer inccidences worldwide
    • Increasing inclination toward personalized medicines
  • Market Restraints
    • High costs of CD antigen therapies
  • Market Opportunities
    • Growing technological advancements in biotechnology that improve the effectiveness of CD antigen therapies
    • Increased government funding and support for cancer research
  • Market Challenges
    • Emergence of alternative technologies associated with CD antigen therapies

Porter's Five Forces: A Strategic Tool for Navigating the CD Antigen Cancer Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the CD Antigen Cancer Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the CD Antigen Cancer Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the CD Antigen Cancer Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the CD Antigen Cancer Therapy Market

A detailed market share analysis in the CD Antigen Cancer Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the CD Antigen Cancer Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the CD Antigen Cancer Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the CD Antigen Cancer Therapy Market

A strategic analysis of the CD Antigen Cancer Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the CD Antigen Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Exelixis, Inc., Genmab A/S, Gilead Sciences, Inc., Illumina, Inc., Incyte Corporation, Jazz Pharmaceuticals PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi, Seagen Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the CD Antigen Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Antibody-Drug Conjugates, Bi-specific T-cell Engagers, Chimeric Antigen Receptor T-cell Therapy, Monoclonal Antibodies, and Radioimmunotherapy.
  • Based on Type of CD Antigens, market is studied across Common Antigens and Emerging Antigens.
  • Based on Type of Cancer, market is studied across Breast Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, and Prostate Cancer.
  • Based on End-user, market is studied across Cancer Treatment Centers, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of a number of cancer inccidences worldwide
      • 5.1.1.2. Increasing inclination toward personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of CD antigen therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing technological advancements in biotechnology that improve the effectiveness of CD antigen therapies
      • 5.1.3.2. Increased government funding and support for cancer research
    • 5.1.4. Challenges
      • 5.1.4.1. Emergence of alternative technologies associated with CD antigen therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Growing usage of antibody-drug conjugates to minimize the impact of the chemotherapy on healthy cells
    • 5.2.2. End-user: Increasing accessibility of CD antigen cancer therapy in cancer treatment centers as they offer comprehensive care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. CD Antigen Cancer Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Antibody-Drug Conjugates
  • 6.3. Bi-specific T-cell Engagers
  • 6.4. Chimeric Antigen Receptor T-cell Therapy
  • 6.5. Monoclonal Antibodies
  • 6.6. Radioimmunotherapy

7. CD Antigen Cancer Therapy Market, by Type of CD Antigens

  • 7.1. Introduction
  • 7.2. Common Antigens
  • 7.3. Emerging Antigens

8. CD Antigen Cancer Therapy Market, by Type of Cancer

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Leukemia
  • 8.4. Lung Cancer
  • 8.5. Lymphoma
  • 8.6. Multiple Myeloma
  • 8.7. Prostate Cancer

9. CD Antigen Cancer Therapy Market, by End-user

  • 9.1. Introduction
  • 9.2. Cancer Treatment Centers
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Specialty Clinics

10. Americas CD Antigen Cancer Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific CD Antigen Cancer Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa CD Antigen Cancer Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Coeptis Therapeutics to Unveil Advances in SNAP-CAR T-Cell Cancer Therapy at SITC 2023
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celgene Corporation
  • 9. Eli Lilly and Company
  • 10. Exelixis, Inc.
  • 11. Genmab A/S
  • 12. Gilead Sciences, Inc.
  • 13. Illumina, Inc.
  • 14. Incyte Corporation
  • 15. Jazz Pharmaceuticals PLC
  • 16. Johnson & Johnson
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Roche Holding AG
  • 22. Sanofi
  • 23. Seagen Inc.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CD ANTIGEN CANCER THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CD ANTIGEN CANCER THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CD ANTIGEN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CD ANTIGEN CANCER THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY BI-SPECIFIC T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COMMON ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY EMERGING ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CD ANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TYPE OF CANCER, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023